Skip to main content
  1. Market Insights
  2. Health
  3. Pharmaceuticals

Vaccines - Haiti

Haiti
  • The Vaccines market in Haiti is expected to achieve a revenue of US$13.01m in 2024.
  • This projection indicates a promising growth potential.
  • Furthermore, the market is anticipated to demonstrate a steady annual growth rate (CAGR 2024-2029) of -2.56%, projecting a market volume of US$11.43m by 2029.
  • It is worth noting that, in a global context, United States is set to generate the highest revenue of US$29.12bn in 2024 within the Vaccines market.
  • Haiti is making significant strides in improving access to vaccines, with increased government initiatives and partnerships with international organizations.

Definition:
This market covers vaccines against infectious diseases. They help to prevent diseases, usually through active immunization. Vaccines against infectious diseases transmitted by viruses (e.g., hepatitis A and B or COVID-19) and bacteria (e.g., typhoid fever or meningococcus) are included.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Pfizer, GlaxoSmithKline, Merck & Co, Sanofi, Moderna, AstraZeneca

In-Scope

  • Vaccines against infectious diseases
  • Prophylactic and therapeutic vaccines
  • Flu vaccines
  • COVID-19 vaccines

Out-Of-Scope

  • Sera and gammaglobulins
  • Antivirals
  • Antibiotics
Vaccines: market data & analysis - Cover

Market Insights report

Vaccines: market data & analysis

Study Details

    Revenue

    Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.

    Most recent update: Mar 2024

    Analyst Opinion

    Haiti, a Caribbean country with a population of over 11 million, has been facing various health challenges, including vaccine-preventable diseases. The vaccines market in Haiti has been developing in response to these challenges and the efforts of the government and international organizations to improve the country's healthcare system.

    Customer preferences:
    Haiti has a high burden of vaccine-preventable diseases such as measles, polio, and cholera. As a result, the demand for vaccines is high, especially among children and vulnerable populations. However, there is still a need for more awareness and education on the importance of vaccination in the country.

    Trends in the market:
    The vaccines market in Haiti has been growing in recent years due to the efforts of the government and international organizations to improve the country's healthcare system. The introduction of new vaccines, such as the HPV vaccine, has also contributed to the growth of the market. However, there are still challenges in vaccine distribution and accessibility, particularly in rural areas.

    Local special circumstances:
    Haiti has been facing various challenges in its healthcare system, including a shortage of healthcare workers, inadequate infrastructure, and limited funding. These challenges have affected the distribution and accessibility of vaccines in the country, particularly in rural areas. The country has also been facing political instability, which has further affected its healthcare system.

    Underlying macroeconomic factors:
    Haiti is one of the poorest countries in the Western Hemisphere, with a GDP per capita of less than $900. The country has been heavily reliant on foreign aid and loans, which has affected its healthcare system. The government has been working to improve the country's healthcare system, but there is still a need for more investment in healthcare infrastructure and human resources. The COVID-19 pandemic has also affected the country's healthcare system and vaccine distribution efforts.

    Global Comparison

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Methodology

    Data coverage:

    Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

    Modeling approach / Market size:

    Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

    Forecasts:

    In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

    Additional notes:

    Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

    Health

    Access more Market Insights on Health topics with our featured report

    Vaccines: market data & analysis - BackgroundVaccines: market data & analysis - Cover

    Key Market Indicators

    Notes: Based on data from IMF, World Bank, UN and Eurostat

    Most recent update: Sep 2024

    Source: Statista Market Insights

    Explore more high-quality data on related topic

    Coronavirus (COVID-19): vaccines and vaccination campaign

    As of March 2023, more than 13 billion COVID-19 vaccine doses had been administered worldwide. Wide-spread vaccine availability, increasing herd immunity, and lower case numbers led to renewed hope and a feeling of normality in 2023. However, especially during the winter seasons and with the potential emergence of new variants of the virus (like Omicron in 2021-2022), tracking of coronavirus cases repeatedly becomes a focus for the public. Thus, there is a level of uncertainty about what developments the winter season 2023/2024 might bring.
    More data on the topic

    Contact

    Get in touch with us. We are happy to help.